ValuEngine Upgrades Neos Therapeutics, Inc. (NASDAQ:NEOS) to Sell
Neos Therapeutics, Inc. (NASDAQ:NEOS) was upgraded by ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Saturday.
NEOS has been the subject of several other reports. Zacks Investment Research upgraded Neos Therapeutics from a “sell” rating to a “hold” rating and set a $8.75 price target for the company in a research note on Wednesday, May 17th. Cantor Fitzgerald set a $20.00 price target on Neos Therapeutics and gave the stock a “buy” rating in a research note on Wednesday. BMO Capital Markets restated an “outperform” rating and issued a $15.00 price target on shares of Neos Therapeutics in a research note on Tuesday, June 20th. Finally, Royal Bank Of Canada set a $12.00 price target on Neos Therapeutics and gave the stock an “outperform” rating in a research note on Tuesday. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. Neos Therapeutics presently has a consensus rating of “Hold” and an average target price of $14.00.
Neos Therapeutics (NASDAQ NEOS) traded up 2.13% during mid-day trading on Friday, reaching $7.20. 465,980 shares of the company were exchanged. Neos Therapeutics has a one year low of $4.85 and a one year high of $9.60. The stock has a 50-day moving average price of $6.96 and a 200 day moving average price of $6.97. The company’s market capitalization is $196.99 million.
Neos Therapeutics (NASDAQ:NEOS) last posted its quarterly earnings results on Tuesday, August 8th. The company reported ($0.83) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.83). Neos Therapeutics had a negative return on equity of 611.78% and a negative net margin of 511.74%. The business had revenue of $4.91 million during the quarter. Analysts predict that Neos Therapeutics will post ($3.20) EPS for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. State of Wisconsin Investment Board purchased a new position in Neos Therapeutics during the second quarter worth approximately $102,000. OMERS ADMINISTRATION Corp purchased a new position in Neos Therapeutics during the second quarter worth approximately $110,000. Mission Wealth Management LLC purchased a new position in Neos Therapeutics during the first quarter worth approximately $122,000. Teachers Advisors LLC increased its position in Neos Therapeutics by 16.3% in the fourth quarter. Teachers Advisors LLC now owns 25,496 shares of the company’s stock worth $149,000 after buying an additional 3,572 shares in the last quarter. Finally, Rhumbline Advisers increased its position in Neos Therapeutics by 13.6% in the second quarter. Rhumbline Advisers now owns 20,409 shares of the company’s stock worth $149,000 after buying an additional 2,441 shares in the last quarter. Hedge funds and other institutional investors own 34.45% of the company’s stock.
About Neos Therapeutics
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Neos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.